AI Article Synopsis

Article Abstract

The structural gene coding for a new endo-beta-1,4-glucanase of Erwinia chrysanthemi strain 3665, previously identified in a cosmid library, was subcloned into pUC18. The gene is expressed from a 1.9 X 10(3)-base-pair insert and its direction of transcription was determined. The properties of the gene product purified from cell-free extracts of Escherichia coli have been studied. The purified protein has an endoglucanase activity but is significantly different from the major endoglucanase Z secreted by E. chrysanthemi strain 3665. The new enzyme was designated as endoglucanase Y and the related gene celY. In E. coli, most of the endoglucanase activity was found in the periplasmic space.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1432-1033.1987.tb10602.xDOI Listing

Publication Analysis

Top Keywords

erwinia chrysanthemi
8
chrysanthemi strain
8
strain 3665
8
endoglucanase activity
8
characterization endoglucanase
4
endoglucanase erwinia
4
chrysanthemi structural
4
gene
4
structural gene
4
gene coding
4

Similar Publications

Article Synopsis
  • L-asparaginases are enzymes that convert L-asparagine into L-aspartic acid and ammonia, and they are important in the pharmaceutical industry, particularly for cancer treatments.
  • Scientists are exploring yeast-derived L-asparaginases as an alternative to bacterial ones, which can cause adverse immune responses.
  • The study focuses on a specific yeast enzyme, Lachancea thermotolerans, demonstrating that a mutant form of this enzyme shows increased activity and significant antileukemic potential compared to commercial bacterial versions.
View Article and Find Full Text PDF

Polyethylene-glycolated -derived l-asparaginase (pegaspargase, pASP) is an essential component of paediatric-inspired regimens for the treatment of acute lymphoblastic leukaemia/lymphoma; nonetheless, is characterised by severe and potentially life-threatening toxicities, such as hypertriglyceridemia. Grades 3-4 events have been reported in ~1%-18% of paediatric patients and in sparse reports in adults. There is limited evidence on the safety of asparaginase rechallenge in patients experiencing severe pASP-related hypertriglyceridemia.

View Article and Find Full Text PDF

Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease without meaningful therapeutic options beyond the first salvage therapy. Targeting PDAC metabolism through amino acid restriction has emerged as a promising new strategy, with asparaginases, enzymes that deplete plasma glutamine and asparagine, reaching clinical trials. In this study, we investigated the anti-PDAC activity of the asparaginase formulation Pegcrisantaspase (PegC) alone and in combination with standard-of-care chemotherapeutics.

View Article and Find Full Text PDF

L-asparaginase is an essential drug used to treat acute lymphoid leukemia (ALL), a cancer of high prevalence in children. Several adverse reactions associated with L-asparaginase have been observed, mainly caused by immunogenicity and allergenicity. Some strategies have been adopted, such as searching for new microorganisms that produce the enzyme and applying protein engineering.

View Article and Find Full Text PDF

Desirable L-asparaginases for treating cancer and current research trends.

Front Microbiol

March 2024

Department of Industrial Biotechnology, Institute of Biotechnology, University of Gondar, Gondar, Ethiopia.

Amino acid depletion therapy is a promising approach for cancer treatment. It exploits the differences in the metabolic processes between healthy and cancerous cells. Certain microbial enzymes induce cancer cell apoptosis by removing essential amino acids.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!